CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Tiziana Life Sciences Ltd

TLSA
$146M
Micro Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON, ENGLAND9 employees

Drugs in Pipeline

4

Phase 3 Programs

0

Upcoming Catalysts

1

Next Catalyst

Q2 2027

Market Overview

Stock performance and key metrics

TLSA News
Catalyst Timeline

2 upcoming, 0 past

Phase 2Next
Positive

Phase 2 — intranasal foralumab

Sep 30, 2026

For non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Tiziana Life Sciences completed patient enrollment in a Phase 2a trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis, with topline data expected in late Q3 2026.

Reduction in brain inflammation demonstrated via quantitative PET imaging in third MSA patient

Source

1 more catalyst beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Tiziana Life Sciences Ltd's drug pipeline?

CatalystAlert tracks 4 drug candidates in Tiziana Life Sciences Ltd's (TLSA) pipeline across Phase 2. Its lead program is Foralumab Nasal (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Tiziana Life Sciences Ltd's next FDA catalyst?

Tiziana Life Sciences Ltd's (TLSA) next tracked catalyst is a Phase 2 expected April 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TLSA biotech catalysts?

Add TLSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tiziana Life Sciences Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply